- Home
- RIGL vs KURA Comparison
RIGL vs KURA Comparison
Compare RIGL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | KURA |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 1.1B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RIGL | KURA |
|---|---|---|
| Price | $45.86 | $11.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $45.67 | $25.56 |
| AVG Volume (30 Days) | 206.3K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | $12.75 | $106.37 |
| P/E Ratio | $34.00 | ★ N/A |
| Revenue Growth | ★ 64.15 | 25.24 |
| 52 Week Low | $24.84 | $7.36 |
| 52 Week High | $52.24 | $13.90 |
Technical Indicators
Market Signals| Indicator | RIGL | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 45.46 |
| Support Level | $40.05 | $8.45 |
| Resistance Level | $49.50 | $12.22 |
| Average True Range (ATR) | 1.45 | 0.46 |
| MACD | -0.61 | -0.26 |
| Stochastic Oscillator | 17.89 | 15.72 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.